Core Viewpoint - The announcement by Baicheng Pharmaceutical regarding the lifting of restrictions on 39,600,000 shares, which constitutes 36.25% of the company's total share capital, is significant as it will allow these shares to be traded starting June 20, 2025 [1]. Share Structure Summary - The total share capital before the IPO was 81,125,000 shares, which increased to 108,166,667 shares post-IPO. The shares without trading restrictions account for 23.95% of the total post-IPO shares, while those with restrictions account for 76.05% [1]. - The shareholders applying for the lifting of restrictions include Shao Chunneng, Lou Jinfang, You Minwei, and three investment partnerships, with Shao Chunneng and Lou Jinfang being the controlling shareholders [1][2]. Financial Performance Summary - Baicheng Pharmaceutical's IPO raised a total of 2.153 billion yuan, with a net amount of 1.863 billion yuan after deducting issuance costs. The actual net fundraising exceeded the initial plan by 1.213 billion yuan [5]. - For Q1 2025, the company reported a revenue of 129 million yuan, a decrease of 40.32% year-on-year, and a net loss attributable to shareholders of 26.2 million yuan, down 152.59% year-on-year [5][6]. - In 2024, the company achieved a revenue of 802 million yuan, a decline of 21.18% compared to 2023, with a net loss of 52.7 million yuan, representing a 119.39% decrease year-on-year [7].
破发连亏股百诚医药3960万股解禁 上市即巅峰超募12亿